Galmed's NASH Candidate Shows Clinically Significant Effect On Fibrosis Improvement

Galmed Pharmaceuticals Ltd GLMD has announced histology and biomarkers analysis results from the Ongoing Open-Label Part of the ARMOR Phase 3 study of Aramchol in NASH and liver fibrosis stage 1 3 patients.
Galmed previously announced a substantial effect on fibrosis improvement in the 16 first patients.
New analyses of biomarkers corroborate the effect showing statistically significant reductions in biomarkers associated with liver fibrosis.
Histology data from the first 20 patients showed that 300mg BID resulted in clinically significant greater histological improvement in 12 out of 20 (60%) patients.
Data is corroborated by biomarkers associated with liver fibrosis in approximately 50 patients providing the potential to predict similar histology responses in a larger cohort.
Galmed also reported a smaller than expected Q3 loss of $(0.31), beating the consensus of $(0.36).
Cash and cash equivalents, restricted cash, and marketable debt securities totaled $42.0 million.
Price Action: GLMD shares are up 4.43% at $2.92 during the market session on the last check Monday.